Perfect 👍 thanks for dropping the Cardarine draft. It’s solid, but it repeats itself a bit and reads more like a research abstract than a polished catalog/product profile. I’ve restructured and paraphrased it in the same professional style we’ve been building, so it’s sharper, benefit-driven, and consistent with your other entries:

---

Cardarine (GW-501516) – PPARδ Agonist for Endurance & Fat Metabolism

🔎 Product Overview

Cardarine (GW-501516) is a powerful PPARδ agonist originally developed by Ligand Pharmaceuticals and GlaxoSmithKline to address metabolic syndrome, obesity, and cardiovascular disease. While discontinued after long-term safety studies, it continues to attract attention in research for its unique ability to optimize fat metabolism, enhance endurance, and support cardiovascular performance.

Unlike SARMs, Cardarine is non-hormonal, meaning it does not suppress testosterone. This makes it a popular option for stacking with SARMs or using independently in studies focused on fat loss, energy efficiency, and athletic endurance.

---

💊 Key Details

• Compound: GW-501516 (Cardarine / Endurobol)
• Category: PPARδ Agonist (non-SARM)
• Form: Oral – high bioavailability
• Originally developed for: Metabolic & cardiovascular health

---

💪 Research Highlights & Benefits

• Enhances endurance & aerobic capacity (VO2 max improvement)
• Boosts fat oxidation by shifting energy use from glucose to fatty acids
• Supports lean muscle retention during caloric restriction
• Non-hormonal mechanism – no testosterone suppression
• May promote cardiovascular and lipid health

---

📦 Common Research Applications

• Endurance performance & stamina studies
• Fat oxidation & weight management research
• Cutting & recomposition protocols
• Cardiovascular conditioning & metabolic health support

---

⚠️ Disclaimer: Cardarine (GW-501516) is a research chemical and not approved for human consumption. It is intended for laboratory research purposes only.